vs
Autonomix Medical, Inc.（AMIX）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-3.0M）
Autonomix Medical是一家专注于心脏电生理领域的医疗科技企业，主要开发用于心律失常诊断与治疗的微创医疗设备，服务北美、欧洲地区的医疗机构与患者，致力于提升心律相关心脏疾病的诊疗效率与效果。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
AMIX vs GMED — 直观对比
营收规模更大
GMED
是对方的Infinity倍
$0
自由现金流更多
GMED
多$205.4M
$-3.0M
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $826.4M |
| 净利润 | $-3.3M | $140.6M |
| 毛利率 | — | 68.4% |
| 营业利润率 | — | 20.5% |
| 净利率 | — | 17.0% |
| 营收同比 | — | 25.7% |
| 净利润同比 | -20.2% | 430.4% |
| 每股收益（稀释后） | — | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMIXGMED
| Q4 25 | $0 | $826.4M | ||
| Q3 25 | $0 | $769.0M | ||
| Q2 25 | $0 | $745.3M | ||
| Q1 25 | $0 | $598.1M | ||
| Q4 24 | $0 | $657.3M | ||
| Q3 24 | $0 | $625.7M | ||
| Q2 24 | $0 | $629.7M | ||
| Q1 24 | — | $606.7M |
净利润AMIXGMED
| Q4 25 | $-3.3M | $140.6M | ||
| Q3 25 | $-7.5M | $119.0M | ||
| Q2 25 | $-3.3M | $202.8M | ||
| Q1 25 | $-3.2M | $75.5M | ||
| Q4 24 | $-2.7M | $26.5M | ||
| Q3 24 | $-2.8M | $51.8M | ||
| Q2 24 | $-2.7M | $31.8M | ||
| Q1 24 | — | $-7.1M |
毛利率AMIXGMED
| Q4 25 | — | 68.4% | ||
| Q3 25 | — | 67.2% | ||
| Q2 25 | — | 66.6% | ||
| Q1 25 | — | 67.3% | ||
| Q4 24 | — | 59.9% | ||
| Q3 24 | — | 56.8% | ||
| Q2 24 | — | 58.7% | ||
| Q1 24 | — | 60.2% |
营业利润率AMIXGMED
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 10.2% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 1.3% |
净利率AMIXGMED
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 5.0% | ||
| Q1 24 | — | -1.2% |
每股收益（稀释后）AMIXGMED
| Q4 25 | — | $1.01 | ||
| Q3 25 | — | $0.88 | ||
| Q2 25 | — | $1.49 | ||
| Q1 25 | — | $0.54 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | — | $0.38 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.9M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $4.6B |
| 总资产 | $10.2M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMIXGMED
| Q4 25 | $9.9M | $557.2M | ||
| Q3 25 | $7.5M | $18.8M | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $11.8M | $890.1M | ||
| Q3 24 | $5.2M | $71.9M | ||
| Q2 24 | $6.8M | $82.5M | ||
| Q1 24 | — | $80.4M |
股东权益AMIXGMED
| Q4 25 | $8.6M | $4.6B | ||
| Q3 25 | $6.4M | $4.4B | ||
| Q2 25 | $7.0M | $4.3B | ||
| Q1 25 | $8.1M | $4.1B | ||
| Q4 24 | $9.7M | $4.2B | ||
| Q3 24 | $3.0M | $4.1B | ||
| Q2 24 | $5.3M | $4.0B | ||
| Q1 24 | — | $3.9B |
总资产AMIXGMED
| Q4 25 | $10.2M | $5.3B | ||
| Q3 25 | $7.9M | $5.1B | ||
| Q2 25 | $9.0M | $5.0B | ||
| Q1 25 | $9.8M | $4.7B | ||
| Q4 24 | $12.0M | $5.3B | ||
| Q3 24 | $5.4M | $5.1B | ||
| Q2 24 | $7.1M | $5.0B | ||
| Q1 24 | — | $4.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.0M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $202.4M |
| 自由现金流率自由现金流/营收 | — | 24.5% |
| 资本支出强度资本支出/营收 | — | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | — | $588.8M |
8季度趋势，按日历期对齐
经营现金流AMIXGMED
| Q4 25 | $-3.0M | $248.6M | ||
| Q3 25 | $-3.8M | $249.7M | ||
| Q2 25 | $-2.6M | $77.9M | ||
| Q1 25 | $-2.6M | $177.3M | ||
| Q4 24 | $-2.3M | $210.3M | ||
| Q3 24 | $-1.6M | $203.7M | ||
| Q2 24 | $-1.9M | $54.3M | ||
| Q1 24 | — | $52.4M |
自由现金流AMIXGMED
| Q4 25 | $-3.0M | $202.4M | ||
| Q3 25 | — | $213.9M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | $-2.3M | $193.2M | ||
| Q3 24 | — | $161.7M | ||
| Q2 24 | $-1.9M | $26.5M | ||
| Q1 24 | — | $23.8M |
自由现金流率AMIXGMED
| Q4 25 | — | 24.5% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 23.6% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 4.2% | ||
| Q1 24 | — | 3.9% |
资本支出强度AMIXGMED
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 4.7% |
现金转化率AMIXGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMIX
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
